D
Healthcare Drug Development

Clinical Trial Efficiency

Published:
Jun 15, 2026
Updated:
May 17, 2026

Short answer

Phase II represents the highest failure risk at 69% attrition

Source: ClinicalTrials.gov

Key findings

  • Phase II represents the highest failure risk at 69% attrition
  • AI-assisted trial design reducing Phase III duration by 25%
  • Decentralized trials improving patient recruitment by 40%

Download AI-ready context

Free

Get a structured Markdown file with key findings, chart data, sources, caveats, and prompts for AI research. Built for Clinical Trial Efficiency.

Context file preview

The downloaded Markdown file includes:

  • Key findings
  • Data table
  • Methodology
  • Source links
  • Suggested AI prompts 
# Clinical Trial Efficiency

## Research Question
## Short Answer
## Key Findings
## Data Table
## How To Use This With AI
## Suggested Prompts
## Sources
## Caveats

Data table

Clinical Trial Efficiency — data table
cost phase duration successRate
4 Phase I 12 63
13 Phase II 28 31
62 Phase III 36 58
8 Phase IV 24 90

Analysis

Clinical trial efficiency remains the pharmaceutical industry's biggest bottleneck. Phase II failures account for the majority of drug development waste, with many compounds failing due to efficacy rather than safety. AI-assisted patient selection and decentralized trial designs are showing promise in reducing both duration and cost across all phases.

How to use this with AI

Use this context file to start a research conversation with an AI tool. It includes the key findings, chart data, sources, and caveats so the model starts from structured context instead of a blank prompt.

Use cases

  • Build a market research memo.
  • Create a short executive brief.
  • Compare this topic with another sector or geography.
  • Generate follow-up research questions.
  • Turn the findings into a slide outline.

Suggested prompts

  • Using this Deepstory context, create a market research memo with key findings, strategic implications, risks, and follow-up questions.
  • Using this dataset, explain the trend, identify the likely drivers, and list the caveats that should be checked before making a decision.
  • Turn this research into a 5-slide presentation outline for a business audience.
  • Create 10 follow-up research questions based on the data and identify what additional sources would be useful.

Sources

Source quality:
Primary source
Last reviewed:
Updated May 2026

Caveats

  • This is public-health or market research, not medical advice.
  • This research is based on available public data and should be used as context, not as professional advice. Check source methodology before making decisions.

How relevant was this information?

#clinical-trials #drug-development #efficiency